¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"visual receptor cells"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • receptor internalization
    ¼ö¿ëü³»ÀçÈ­
  • receptor potential
    ¼ö¿ëüÀüÀ§
  • receptor site
    ¼ö¿ëüºÎÀ§
  • receptor stimulant
    ¼ö¿ëüÀÚ±ØÁ¦
  • receptor supersensitivity
    ¼ö¿ëüÃʹΰ¨¼º
  • receptor-ligand interaction
    ¼ö¿ëü¸®°£µå»óÈ£ÀÛ¿ë
  • spare receptor
    ¿©ºÐ¼ö¿ëü
  • scavenger receptor
    û¼ÒÁ¦¼ö¿ëü
  • stretch receptor
    »¸Ä§¼ö¿ë±â, ½ÅÀå¼ö¿ë±â
  • sensory receptor
    °¨°¢¼ö¿ë±â
  • silent receptor
    ¹«¹ÝÀÀ¼ö¿ëü
  • taste receptor
    ¹Ì°¢¼ö¿ë±â
  • T-cell antigen receptor
    T¼¼Æ÷Ç׿ø¼ö¿ëü
  • T-cell receptor
    T¼¼Æ÷¼ö¿ëü
  • tactile receptor
    Ã˰¢¼ö¿ë±â
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 13 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • receptor site
    ¼ö¿ëüºÎÀ§
  • receptor stimulant
    ¼ö¿ëüÀÚ±ØÁ¦
  • receptor supersensitivity
    ¼ö¿ëüÃʹΰ¨¼º
  • sensory receptor
    °¨°¢¼ö¿ëü
  • silent receptor
    ¹«¹ÝÀÀ¼ö¿ëü
  • spare receptor
    ¿©ºÐ¼ö¿ëü
  • stretch receptor
    »¸Ä§¼ö¿ëü, ½ÅÀå¼ö¿ëü
  • T cell antigen receptor
    Ƽ¼¼Æ÷Ç׿ø¼ö¿ëü
  • tactile receptor
    Ã˰¢¼ö¿ëü
  • taste receptor
    ¹Ì°¢¼ö¿ëü
  • tension receptor
    Àå·Â¼ö¿ëü
  • vasopressor receptor
    Ç÷°ü¼öÃà¼ö¿ëü
  • volume receptor
    ¿ëÀû¼ö¿ëü
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • receptor, T cell
    T¼¼Æ÷(Ç׿ø)¼ö¿ëü
  • receptor-ligand interaction
    ¼ö¿ëü-¹èÀ§ÀÚ »óÈ£ÀÛ¿ë
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • visual angle
    ½Ã°¢(ãÊÊÇ)
  • visual angle
    ½Ã°¢(ãÊÊÇ).
  • visual aphasia
    ½Ã°¢¼º ½Ç¾îÁõ(¡­ã÷åÞñø).
  • visual aphasia
    ½Ã°¢¼º ½Ç¾îÁõ(¡­ã÷åÞñø)
  • visual area
    ½Ã°¢¿µ¿ª(çÐæ´).
  • visual association area
    ½Ã°¢¿¬ÇÕ¿µ¿ª
  • visual aura
    ½Ã°¢ÀüÁ¶(ãÊÊÆîñð¼).
  • visual aura
    ½Ã°¢ÀüÁ¶(ãÊÊÆîñð¼)
  • visual axis
    ½ÃÃà(ãÊõî)
  • visual axis
    ½ÃÃà(ãÊõî), ½Ã¼±(ãÊàÊ).
  • visual cell
    ½Ã¼¼Æ÷
  • visual cell
    ½Ã°¢¼¼Æ÷, ½Ã¼¼Æ÷(ãÊá¬øà).
  • visual center
    ½Ã°¢ÁßÃß(ãÊÊÆñéõÒ).
  • visual cone =ocular c.
    ½Ã°¢¿øÃß.
  • visual confusion
    ½Ã°¢È¥¶õ
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 8
EVR evoked visual response; exudative vitreoretinopathy
GVF good visual fields
LVF left ventricular failure; left ventricular function; left visual field; low-voltage fast; low-voltag...
MVPT Motor-Free Visual Perception Test
NVA near visual acuity
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 8
V.C. Visual cortex
VECP Visual evoked cortical potential
A-V auditory-visual
LVF-RH left visual field--right hemisphere
PVER pattern reversal visual evoked response
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
oestrogen receptor <cell biology> Cytoplasmic proteins that bind oestrogens and migrate to the nucleus where they regulate DNA transcription. Evaluation of the state of oestrogen receptors in breast cancer patients has become clinically important and determines the likelihood of response to anti-oestrogen therapy with tamoxifen.
(17 Jul 2002)
olfactory receptor neurons Neurons in the olfactory epithelium with proteins (receptors, odourant) that bind, and thus detect, odourants. Olfactory receptor neurons are bipolar. They send to the surface of the epithelium apical dendrites with non-motile cilia from which project odourant receptor molecules. Their unmyelinated axons synapse in the olfactory bulb of the brain. Unlike other neurons, they can be generated from precursor cells in adults.
(12 Dec 1998)
opiate receptor <pharmacology> Opiate-binding sites found throughout primary afferents and the neuraxis.
(16 Dec 1997)
opioid receptor <pharmacology> A membrane protein, widely distributed in animal cells, but especially in the brain (enkephalin receptors) and gut. The natural ligands are the opiate peptide neurotransmitters, but the name is given because opiates are potent agonists that occupy the receptors and mimic the action of the natural transmitters.
(18 Nov 1997)
T-cell receptor <immunology> The antigen recognising receptor on the surface of T-cells. Heterodimeric (disulphide linked), one of the immunoglobulin superfamily of proteins, binds antigen in association with the major histocompatibility complex (MHC), leading to the activation of the cell.
There are two subunits (_ and _, 42-44 kD in mouse, 50-40 kD in humans), each with variable and constant regions, that are associated noncovalently with T3 (20-30 kD). A second heterodimer on CD3 cells with _ (35 kD in mice, 55 kD in humans) and _ (45 kD in mice, 40 kD in humans) chains is a second T-cell antigen receptor that is not MHC restricted. The __ T-cell receptors (TCRs) are formed on very early T-cells in the thymus.
(18 Nov 1997)
TCK receptor-tyrosine kinase <enzyme> A member of the eph receptor tyrosine kinase subfamily; expressed during xenopus development; shows 79% amino acid identity to hek2; genbank l43621
Registry number: EC 2.7.1.-
Synonym: tck protein
(26 Jun 1999)
TGF-beta receptor protein kinase <enzyme> Belongs to the receptor-type serine-threonine kinase subfamily; from chick embryo, related to type II receptor for tgf-beta; 502 aa residues, mw 56,766 da; aa sequence given in first source
Registry number: EC 2.7.1.-
Synonym: tgf-beta rpk, rpk-1, rpk-2
(26 Jun 1999)
early receptor potential A voltage arising across the eye from a charge displacement within photoreceptor pigment, in response to an intense flash of light.
(05 Mar 2000)
thyroid receptor antibody A test that measures the amount of an antibody (thyroid stimulating antibody) which is directed against a receptor for TSH on the thyroid gland. This antibody acts like TSH and stimulates the thyroid to produce excessive amounts of thyroid hormone. The presence of this antibody generally indicates Grave's disease (hyperthyroidism).
(27 Sep 1997)
TIE-2 receptor tyrosine kinase <enzyme> Expressed in developing vascular endothelial cells; unlike tie-1, also expressed in lens epithelium and heart epicardium; has the same organization of amino acid sequence motifs characteristic of tie-1; aa sequence of the intracellular and extracellular regions of tie-1 and tie-2 are 79% and 32% identical, respectively; aa sequence of both kinases given in first source
Registry number: EC 2.7.10.-
Synonym: tie-2-rtk
(26 Jun 1999)
tie receptor tyrosine kinase <enzyme> From human leukaemia cells; expressed in developing vascular endothelial cell; has homology with egf, bfgf, csf-1, pdgf and stem cell factor receptors; ligand and biologic function not known as of 12/92; tie-1 receptor tyrosine kinase is rat homolog of tie receptor tyrosine kinase; aa sequence known
Registry number: EC 2.7.10.-
Synonym: tie-1 receptor tyrosine kinase, tie-1 rtk
(26 Jun 1999)
endothelin receptor Simple squamous epithelium lining blood vessels, lymphatics and other fluid filled cavities (such as the anterior chamber of the eye). Mesodermally derived, unlike most epithelia.
(18 Nov 1997)
epidermal growth factor receptor protein-tyrosine kinase <enzyme> The catalytic protein-tyrosine kinase domain found on the cytoplasmic beta-portion of epidermal growth factor receptor.
Registry number: EC 2.7.1.-
(12 Dec 1998)
estradiol receptor tyrosine kinase <enzyme> Calcium and calmodulin dependent
Registry number: EC 2.7.1.-
Synonym: ertk
(26 Jun 1999)
kainate receptor A type of glutamate receptor that participates in excitatory neurotransmission and also binds kainate and acts as a cation channel; injection of kainate causes death of neurons but preserves glial cells and axons.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 8
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 8
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 8
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 8
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 8
ÅëÇÕ°Ë»ö ¿Ï·á